In drug development, understanding how mature and newly produced proteins are affected by drugs is vital to elucidate the potential effects of the drug and to determine the specificity of the drug by only targeting the proteins of interest. Proteome Dynamics Profiling provides a reliable overview of the proteins affected by your intervention.
By utilizing Stable Isotope Labeling by Amino acids in Cell culture (SILAC) in drug development studies, it is possible to determine which proteins are mature when adding a drug and which are newly produced. By tracking how the proteins are affected, we can determine which mature proteins are degraded or stabilized. Similarly, by tracking the newly produced proteins, we can determine which proteins demonstrate an enhanced or reduced production following the application of the drug.
Proteome Dynamics Profiling is an excellent choice for early verification of potential drug candidates or other interventions. The distinction between mature and nascent proteins gives a more granular overview than ordinary global proteomics experiments.
If you’d like to learn more, we are happy to discuss your project and help you get the most out of your drug candidates.
SILAC-based
mature vs. newly produced proteins
Up to 10,000 proteins
across your samples
Eclipse + FAIMS + Evosep
fast and robust workflow
At Biogenity, we understand that performing new assays are complex. As a part of our Proteome Dynamics Profiling workflow, we ensure that you understand all the steps along the way and provide guidance and protocols as needed, ensuring your project not only succeeds but also contributes to your scientific venture.
We invite you to an online consultation, during which we can address your questions and offer an expert assessment of how our drug development strategies can be customized to meet your research goals.
Biogenity's team is experienced in working with different approaches, and we always offer a free consultation to discuss how dynamic proteome profiling or other workflows fit your research aim. At Biogenity, we care, which is why it is essential for us to understand your study to ensure that we provide you with the best approach for your research.
Biogenity’s team works with the highest standards to ensure the best quality handling and analysis of your samples. We ensure that every aspect of the workflow is executed by specialized personnel.
Proteome dynamics profiling relies on deep and reproducible quantification of both mature and newly produced proteins. Biogenity combines high-end Orbitrap instrumentation with fast chromatography to give you the depth needed to see how your intervention affects the proteome.
The Orbitrap Eclipse Tribrid mass spectrometer combined with FAIMS and Evosep One provides a fast and robust workflow, enabling us to monitor up to 10,000 proteins across your samples. Hence, you get a deep understanding of how even low-abundant proteins are affected by your intervention.
At Biogenity, we know that data analysis is crucial to understanding the impact of your intervention. That's why we provide you with an easy-to-follow report detailing the reliably and significantly changing proteins. We walk you through the figures step-by-step, together with a folder containing all tables and figures.
Biogenity's data analysis can be tailored to different research aims, from machine learning and statistics on biomarkers to validating peptide spectra, uncovering new mutations, and establishing degradation motifs. We always strive to provide you with the right tools to understand the data and communicate your findings.
At the conclusion of your proteome dynamics profiling for drug development analysis, we ensure a seamless transition from discovery to application. We deliver detailed reports and data, followed by a post-delivery consultation to discuss your study's insights and findings.
What to expect during post-consultation:
Together, we ensure that you have the best prerequisite for your further research. The consultation can also be used to explore the next step, whether you are looking to expand the project with additional omics studies or validate the results.